{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vemurafenib+%28Zelboraf%C2%AE%29", "query": { "intervention": "Vemurafenib (Zelboraf®)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vemurafenib+%28Zelboraf%C2%AE%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T03:43:46.907Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01841463", "title": "Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Inoperable Malignant Melanoma With BRAF Mutation" ], "interventions": [ { "name": "P1446A-05", "type": "DRUG" }, { "name": "Vemurafenib (Zelboraf®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Piramal Enterprises Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2013-08", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2014-09-04", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 4, "location_summary": "South San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 1 more", "locations": [ { "city": "South San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01841463" }, { "nct_id": "NCT01767623", "title": "A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-08-20", "completion_date": "2017-04-20", "has_results": false, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 1, "location_summary": "Encinitas, California", "locations": [ { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01767623" }, { "nct_id": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "SBRT", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2020-11-06", "completion_date": "2030-05-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 38, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 28 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04302025" }, { "nct_id": "NCT03013491", "title": "PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "CX-072", "type": "DRUG" }, { "name": "ipilimumab", "type": "DRUG" }, { "name": "vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytomX Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2017-01-19", "completion_date": "2020-10-27", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 16, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013491" }, { "nct_id": "NCT01006980", "title": "A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 675, "start_date": "2010-01", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-09-28", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01006980" }, { "nct_id": "NCT01596140", "title": "Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Solid Tumor" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 27, "start_date": "2012-12-18", "completion_date": "2020-06-01", "has_results": false, "last_update_posted_date": "2020-06-04", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01596140" }, { "nct_id": "NCT01286753", "title": "A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2011-06", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2016-09-07", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 9, "location_summary": "Torrance, California • New Haven, Connecticut • Chicago, Illinois + 5 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01286753" }, { "nct_id": "NCT02693535", "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Multiple Myeloma", "Advanced Solid Tumors" ], "interventions": [ { "name": "Sunitinib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Olaparib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Abemaciclib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Talazoparib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Futibatinib", "type": "DRUG" }, { "name": "Dabrafenib plus Trametinib", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Society of Clinical Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 4200, "start_date": "2016-03-14", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 174, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02693535" }, { "nct_id": "NCT01673854", "title": "Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Vemurafenib", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 70, "start_date": "2012-09-13", "completion_date": "2015-05-12", "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 14, "location_summary": "Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 8 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01673854" }, { "nct_id": "NCT02721459", "title": "XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Skin Cancer" ], "interventions": [ { "name": "XL888", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2016-09-07", "completion_date": "2026-11-04", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-04T03:43:46.907Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02721459" } ] }